

BRAINSTORM CELL THERAPEUTICS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

HACKENSACK, N.J. and PETACH TIKVAH, ISRAEL – November 17, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2015.

“2015 continues to be a year of important advances in our clinical and corporate programs,” stated BrainStorm’s CEO, Chaim Lebovits. “Specifically, we are making significant progress in the ongoing Phase II study of our lead development candidate, NurOwn®, for the treatment of patients with amyotrophic lateral sclerosis (ALS). Of particular note, in August, we completed enrollment in the randomized, double-blind, placebo-controlled, Phase II clinical trial of NurOwn, being conducted at three major academic medical centers in the U.S. We are pleased to have rapidly achieved this milestone and anticipate reporting top-line results from the trial prior to the end of the second quarter of 2016.”

Mr. Lebovits continued, “Additionally, we were pleased to have recently reported on the successful completion of the Data and Safety Monitoring Board’s (DSMB) second review of our going NurOwn Phase II program. Importantly, the DSMB identified no safety concerns, and recommended that the Phase II study of NurOwn in ALS should continue as planned. Reviewing data related to 47 of the 48 enrolled patients, the DSMB did not identify any adverse events, lab abnormalities or significant protocol deviations that would be cause for concern related to the safety or tolerability of either the intrathecal or intramuscular injections.”

“We also strengthened our senior team with the addition of Yoram Bibring as Chief Financial Officer at the end of the July,” continued Mr. Lebovits. “Mr. Bibring brings decades of experience as a senior financial officer at leading biopharmaceutical, healthcare and software companies in the U.S. and Israel. He has experience creating shareholder value and we welcome his unique knowledge-base and abilities.”

“Finally, at the end of September, I was proud to be appointed to the position of Chief Executive Officer of BrainStorm, expanding the role I have played at the company since 2007,” commented Mr. Lebovits. “This is the most important time in the history of BrainStorm, and I am honored to be leading the company into the next phase of its development. Of course I am grateful for the leadership Dr. Tony Fiorino provided when he was in the role, and we are all pleased that he continues with BrainStorm as Chief Medical Advisor to the company.”

“Moving forward,” continued Mr. Lebovits, “we are excited about the potential of our NurOwn technology to improve treatment options for patients with ALS. Our strong financial position,

including our robust cash reserves will provide the financial flexibility for BrainStorm to achieve its planned clinical milestones, including completion of the Phase 2 trial of NurOwn, as well as other product and development stage initiatives.”

Third Quarter 2015 and Recent Highlights

- Successful completion of Data and Safety Monitoring Board review of Phase II clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
- Appointment of Chaim Lebovits as Chief Executive Officer, building on strategic and operational experience, and history of leadership at BrainStorm.
- Completed enrollment in Phase II, randomized, double-blind, placebo-controlled multicenter clinical trial of NurOwn in ALS
- Yoram Bibring named Chief Financial Officer, bringing decades of financial experience.

Financial Results for the Third Quarter Ended September 30, 2015

- Research and development expenses for the three months ended September 30, 2015 were \$1,503,000, compared to \$1,375,000 in the second quarter of 2015 and 1,572,000 in the third quarter of 2014
- General and administrative expenses for the three months ended September 30, 2015 were approximately \$1,068,000, compared to \$988,000 in the second quarter of 2015 and \$858,000 in the third quarter of 2014.
- Loss from operation for the three months ended September 30, 2015 was (\$2,571,000) compared to (\$2,363,000), in the second quarter of 2015 and (\$2,430,000) in the third quarter of 2014
- Net loss for the three months ended September 30, 2015 was (\$2,603,000), or (\$0.14) per share, compared to a net loss of (\$2,265,000), or (\$0.12) per share in the second quarter of 2015 and (\$2,421,000), or (\$0.16) per share in the third quarter of 2014.
- As of September 30, 2015, the company had cash, cash equivalents, and short-term deposits of approximately \$17.2 million, compared to \$8.5 million at December 31, 2014.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial at three major clinical centers in the United States. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Media:

Uri Yablonka

Chief Operating Officer

BRAINSTORM CELL THERAPEUTICS INC.

201-488-0460

uri@brainstorm-cell.com

Investors:

Michael Rice

LIFESCI ADVISORS, LLC

Phone: (646) 597-6979

mrice@lifesciadvisors.com

#